Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study The 6-month discontinuation rates of tamoxifen ...

We assessed whether concomitant use of CYP2D6-inhibiting drugs associates with increased risk of fall injuries after newly initiated therapy with beta-blockers. A case-crossover study design was ...

Life-threatening opioid intoxication developed in a patient after he was given small doses of codeine for the treatment of a cough associated with bilateral pneumonia. Codeine is bioactivated by ...

Owing to its highly polymorphic nature and major contribution to the metabolism and bioactivation of numerous clinically used drugs, CYP2D6 is one of the most extensively studied drug-metabolizing ...

A new in vivo pharmacokinetic recall study involving 114 participants in the Estonian Biobank has provided the first clinical confirmation that previously uncharacterized genetic variants in the ...

For older nursing home (NH) residents, use of CYP2D6-metabolized opioids concomitantly with CYP2D6-inhibiting antidepressants is associated with worsening pain and increased risk of opioid-related ...

In recent years, scientists discovered that an enzyme called CYP2D6 could possibly predict whether a patient would respond to the drug. Small studies aimed at confirming the predictive link, however, ...

Aim We sought to discover endogenous urinary biomarkers of human CYP2D6 activity. Patients & Methods Healthy pediatric subjects (n = 189) were phenotyped using dextromethorphan and randomized for ...

Oral Contraceptives and Breast Cancer Risk in the International BRCA1/2 Carrier Cohort Study: A Report From EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group The CYP3A and CYP2D6 enzymes ...

(A) Transgene structures for the expression of the exogenous FLAG-tagged CYP2D6 protein or the IRES-based co-expression of the human hepatic CYP2D6 and GFP proteins. (B) Phase contrast images of the ...

—New research uncovers a possible link between CYP2D6 activity and the development of tardive dyskinesia in certain patients taking antipsychotics. Reviewed by Nicole Foubister, Clinical Assistant ...

Luminex announced that it has launched its pharmacogenetic test, the xTAG CYP2D6 Kit, which is approved by the FDA to help identify individuals who possess both common and rare CYP2D6 poor-metabolizer ...